
    
      The aim of this study is to determine whether the addition of an augmentation medication
      (topiramate 200mg/d) will confer additional reductions in symptomatology in BN patients who
      have received six weeks of standard pharmacological treatment with fluoxetine 60 mg/day or
      its equivalent and had a partial response but are not in symptomatic remission.
    
  